Abattis Bioceuticals Corp (OTC:ATTBF)

Abattis Bioceuticals Corp., a specialty biotechnology company, focuses on the production, licensing, and marketing of proprietary ingredients and formulas for use in biopharma, nutraceutical, cosmetic, and animal nutrition markets. The company has a portfolio of proprietary products in areas of the functional foods and supplements business. It focuses on refining and marketing a portfolio of proprietary nutraceutical formulations of botanical agents for various strains of human influenza and other viral diseases. The company offers Defenzall, a proprietary formula based on a homeopathic blend of botanicals for the treatment of cold and flu. It also provides products for the treatment of migraine headache; osteoporosis bone health; Hemp, a non-psychoactive products derived from plants of the Cannabis genus; and magnesium oxide (MgO) products for use in any building or facility designed to cultivate botanicals. The company was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corp. in September 2012. Abattis Bioceuticals Corp. was incorporated 1997 and is headquartered in Vancouver, Canada.